Chargement en cours...
COVID‐19: Consider IL‐6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients
COVID‐19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 receptor (IL‐6R) antagonist therapy for the COVID‐19 patients. Two humanized monoclonal antibodies are in clini...
Enregistré dans:
| Publié dans: | J Med Virol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7283789/ https://ncbi.nlm.nih.gov/pubmed/32462717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.26078 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|